Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • Saudi Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Neurosciences Journal
  • Other Publications
    • Saudi Medical Journal
  • My alerts
  • Log in
Neurosciences Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Research ArticleOriginal Article
Open Access

Prevalence and biopsychosocial factors associated with treatment adherence among people with epilepsy in a tertiary care hospital in Riyadh, Saudi Arabia

Amani S. Almwled, Abdulkarim O. Almuhaydili, Saqr M. Altamimi, Muhannad A. Alzahrani, Rodhan K. Alnahdi, Saad B. Almotairi, Bandar N. Aljafen and Fahad D. Alosaimi
Neurosciences Journal April 2022, 27 (2) 94-103; DOI: https://doi.org/10.17712/nsj.2022.2.20210142
Amani S. Almwled
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Abdulkarim O. Almuhaydili
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saqr M. Altamimi
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhannad A. Alzahrani
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodhan K. Alnahdi
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saad B. Almotairi
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bandar N. Aljafen
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fahad D. Alosaimi
From Administration of mental health (Almwled), Makkah, Department of Psychiatry (Alosaimi), College of Medicine (Aljafen), King Saud University, and College of Medicine (Almuhaydili, Altamimi, Alzahrani, Alnahdi, Almotairi), King Saud University, Riyadh, Kingdom of Saudi Arabia.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    Table 1-

    Demographic characteristics of patients with epilepsy.

    CharacteristicsTotal(207)AdherenceNon adherenceP-value
    207N=169(81.6%)N=38(18.4%)
    n(%)n(%)n(%)
    Sex
    Male96(46.4)80(47.3)16(42.1)0.559
    Female111(53.6)89(52.7)22(57.9)
    Age, years(Mean ± SD)34.00(13.48)34.45(13.68)32.00(12.54)0.313
    17-44164(79.2)135(79.9)29(76.3)0.368
    45-5931(15.0)23(13.6)8(21.1)
    >=6012(5.8)11(6.5)1(2.6)
    Nationality
    Saudi199(96.1)162(95.9)37(97.4)0.550
    Non Saudi8(3.9)7(4.1)1(2.6)
    Marital status
    Married104(50.2)87(51.5)17(44.7)0.590
    Single93(44.9)75(44.4)18(47.4)
    Divorced9(4.3)6(3.6)3(7.9)
    Widow1(.5)1(.6)  
    Education level
    University114(55.1)92(54.4)22(57.9)0.003*
    High school72(34.8)65(38.5)7(18.4)
    Intermediate school12(5.8)8(4.7)4(10.5)
    Primary school9(4.3)4(2.4)5(13.2)
    Occupation
    Employed81(39.1)67(39.6)14(36.8)0.572
    Unemployed114(55.1)91(53.8)23(60.5)
    Retired12(5.8)11(6.5)1(2.6)
    Family income
    Less than 500038(18.4)30(17.8)8(21.1)0.596
    5000-1000060(29.0)49(29.0)11(28.9)
    10000-1500054(26.1)42(24.9)12(31.6)
    More than 1500055(26.6)48(28.4)7(18.4)
    Residency
    Inside Riyadh161(77.8)133(78.7)28(73.7)0.502
    Outside Riyadh46(22.2)36(21.3)10(26.3)
    Duration of epilepsy(Mean ± SD)11.95(9.29)12.19(9.40)10.92(8.82)0.450

    *Significant p-value

      • View popup
      Table 2

      - Past psychiatric history of patients. Reasons of not seeing a psychiatrist in the past:

      Suggested reasons:n(%)order
      I do not suffer psychologically and I do not need a psychiatrist158(81.4)1st
      I suffer psychologically, but I need psychological and social support inside the epilepsy center, not going to psychiatric clinics outside the center9(4.6)2nd
      I suffer psychologically, but I think I do not need a psychiatrist6(3.1)3rd
      I suffer psychologically, but I avoid seeing a psychiatrist for fear of society’s perception5(2.6)4th
      I suffer psychologically but I do not have access to a psychiatrist3(1.5) 
      I did not think about it3(1.5) 
      I do not need a psychiatrist because I suffer for short period2(1.0) 
      I suffer psychologically, but I did not think that I would go to a psychiatrist2(1.0) 
      Because I think what I feel is the effects of epilepsy medications2(1.0) 
      Because I think I only need care from my family1(.5) 
      I fear from psychiatric medications side effects1(.5) 
      I left it because I did not benefit from it1(.5) 
      I got help from a life coach1(.5) 
      • View popup
      Table 3

      - Medical history of patients by adherence status.

      VariablesTotalAdherenceNon adherenceP-value
      n(%)n(%)n(%)
      Chronic illnesses
      Hypertension83.974.112.60.550
      Diabetes Mellitus62.963.6000.291
      Asthma125.8105.925.30.876
      Cardiovascular Diseases41.942.4000.441
      Eczema1.51.6000.816
      Hematological diseases1.50012.60.184
      Thyroid diseases1.51.6000.816
      Osteoporosis21.021.2000.660
      Systemic Lupus Erythematosus1.51.6000.816
      Psoriasis1.51.6000.816
      Rheumatoid21.01.612.60.334
      Number16881.213579.93386.80.321
      • View popup
      Table 4

      - Patient psychiatric examinations by adherence status.

      VariablesTotalAdherenceNonadherenceP-value
      n(%)n(%)n(%)
      PHQ9 Score
      Crude mean (± SD)6.31(5.51)5.91(5.26)8.13(6.28)0.024
      Adjusted* mean (± SE)6.97(0.48)5.91(0.40)8.13(0.99)0.034
      PHQ9 depression groups
      Normal (0–9)160(77.3)136(80.5)24(63.2)0.021
      Depression (≥10)47(22.7)33(19.5)14(36.8) 
      GAD7
      Crude mean (± SD)6.37(4.91)5.95(4.63)8.21(5.69)0.027
      Adjusted* mean (± SE)7.05(0.43)5.95(0.35)8.21(0.90)0.014
      GAD7 anxiety groups
      Mild anxiety66(31.9)55(32.5)11(28.9) 
      Moderate anxiety35(16.9)25(14.8)10(26.3) 
      Severe anxiety16(7.7)11(6.5)5(13.2) 
      PHQ15
      Crude mean (± SD)8.19(5.46)7.69(5.23)10.39(5.98)0.006
      Adjusted* mean (± SE)9.00(0.45)7.69(0.38)10.40(0.88)0.005
      PHQ15_CAT
      Minimal63(30.4)55(32.5)8(21.1)<0.001
      Low70(33.8)59(34.9)11(28.9) 
      Medium44(21.3)39(23.1)5(13.2) 
      High30(14.5)16(9.5)14(36.8) 
      ECRM16anxiety
      Crude mean (± SD)27.68(10.68)27.24(10.85)29.61(9.79)0.219
      Adjusted* mean (± SE)28.38(0.96)27.24(0.83)29.61(1.60)0.246
      ECR16 avoidance
      Crude mean (± SD)25.04(8.24)25.23(8.07)24.21(9.04)0.027
      Adjusted* mean (± SE)24.73(0.74)25.23(0.62)24.21(1.47)0.503
      MOCA score
      Crude mean (± SD)22.41(4.06)22.48(4.08)22.11(4.03)0.609
      Adjusted* mean (± SE)22.29(0.37)22.48(0.31)22.11(0.67)0.609
      MOCA cognitive function groups
      Normal56(27.1)45(26.6)11(28.9)0.771
      Cognitive impairment151(72.9)124(73.4)27(71.1) 

      *Mean values were adjusted for age and sex

        • View popup
        Table 5

        - Correlation between epilepsy medications polypharmacy and adherence status.

        VariablesTotalAdherenceNonadherenceP-value
        Number%≥Number(%)Number(%)
        Polypharmacy
        yes polypharmacy6029.2749(29.34)11(28.95)0.962
        No polypharmacy14570.73118(70.66)27(71.05)
        Levetiracetam
        Yes11555.5690(53.25)25(65.79)0.160
        No9244.4479(46.75)13(34.21)
        Valproic Acid
        Yes2110.1417(10.06)4(10.53)0.931
        No18689.86152(89.94)34(89.47)
        Carbamazepine
        Yes5828.0246(27.22)12(31.58)0.589
        No14971.98123(72.78)26(68.42)
        Lamotrigine
        Yes2411.5923(13.61)1(2.63)0.040*
        No18388.41146(86.39)37(97.37)
        Phenytoin
        Yes41.934(2.37)0(0.00)0.441
        No20398.07165(97.63)38(100.00)
        Topiramate
        Yes52.423(1.78)2(5.26)0.228
        No20297.58166(98.22)36(94.74)
        Clonazepam
        Yes10.481(0.59)0(0.00)0.816
        No20699.52168(99.41)38(100.00)
        Lacosamide
        Yes52.425(2.96)0(0.00)0.359
        No20297.58164(97.04)38(100.00)
        Phenobarbital
        Yes10.481(0.59)0(0.00)0.816
        No20699.52168(99.41)38(100.00)

        Significant p-value

          • View popup
          Table 6

          - Univariate analysis examining the relationship between variables and Visual Analogue Scale of treatment adherence.

          VariablesBetaStandard errorP-value
          Age0.0150.0080.068
          Sex (female vs male)-0.1990.2260.380
          Disease duration0.0200.0120.109
          PHQ9-0.0520.0200.011
          GAD7-0.0640.0230.005
          PHQ15-0.0710.0200.001
          ECR-Anxious-0.0170.0110.104
          ECR-Avoidant-0.0080.0140.548
          Family history of epilepsy-0.0260.2530.918
          Supernatural belief-0.0990.2740.719
          Past psychiatric illness-0.2200.8210.789
          Marital status (married vs not married)0.2030.2260.369
          Education (bachelor or higher vs lower than Bachelor’s degree)-0.0420.2270.854
          Employment status(unemployed vs employed)-0.1770.2310.445
          MOCA score-0.0110.0280.704
          • View popup
          Table 7

          - Multivariate regression analysis examining the relationship between variables and Visual Analogue Scale of treatment adherence.

          VariablesEstimateStandard errorP-value
          Age0.1320.0080.058
          Sex0.0460.2380.533
          PHQ9 Score-0.0120.0300.910
          PHQGAD7 Score-0.0520.0350.624
          PHQ15-0.2180.0280.020
        PreviousNext
        Back to top

        In this issue

        Neurosciences Journal: 27 (2)
        Neurosciences Journal
        Vol. 27, Issue 2
        1 Apr 2022
        • Table of Contents
        • Cover (PDF)
        • Index by author
        Print
        Download PDF
        Email Article

        Thank you for your interest in spreading the word on Neurosciences Journal.

        NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

        Enter multiple addresses on separate lines or separate them with commas.
        Prevalence and biopsychosocial factors associated with treatment adherence among people with epilepsy in a tertiary care hospital in Riyadh, Saudi Arabia
        (Your Name) has sent you a message from Neurosciences Journal
        (Your Name) thought you would like to see the Neurosciences Journal web site.
        Citation Tools
        Prevalence and biopsychosocial factors associated with treatment adherence among people with epilepsy in a tertiary care hospital in Riyadh, Saudi Arabia
        Amani S. Almwled, Abdulkarim O. Almuhaydili, Saqr M. Altamimi, Muhannad A. Alzahrani, Rodhan K. Alnahdi, Saad B. Almotairi, Bandar N. Aljafen, Fahad D. Alosaimi
        Neurosciences Journal Apr 2022, 27 (2) 94-103; DOI: 10.17712/nsj.2022.2.20210142

        Citation Manager Formats

        • BibTeX
        • Bookends
        • EasyBib
        • EndNote (tagged)
        • EndNote 8 (xml)
        • Medlars
        • Mendeley
        • Papers
        • RefWorks Tagged
        • Ref Manager
        • RIS
        • Zotero
        Share
        Prevalence and biopsychosocial factors associated with treatment adherence among people with epilepsy in a tertiary care hospital in Riyadh, Saudi Arabia
        Amani S. Almwled, Abdulkarim O. Almuhaydili, Saqr M. Altamimi, Muhannad A. Alzahrani, Rodhan K. Alnahdi, Saad B. Almotairi, Bandar N. Aljafen, Fahad D. Alosaimi
        Neurosciences Journal Apr 2022, 27 (2) 94-103; DOI: 10.17712/nsj.2022.2.20210142
        Twitter logo Facebook logo Mendeley logo
        • Tweet Widget
        • Facebook Like
        • Google Plus One
        Bookmark this article

        Jump to section

        • Article
          • Abstract
          • Methods
          • Results
          • Discussion
          • Acknowledgement
          • References
        • Figures & Data
        • eLetters
        • References
        • Info & Metrics
        • PDF

        Related Articles

        • No related articles found.
        • PubMed
        • Google Scholar

        Cited By...

        • No citing articles found.
        • Google Scholar

        More in this TOC Section

        • Motherhood and pregnancy concerns of Saudi females with multiple sclerosis in Riyadh city: A quantitative analysis
        • Ranking the difficulty of the cognitive tasks in Dual-Tasks during walking in healthy adults
        • Exploring physiotherapist’s ability to identify cauda equina syndrome early
        Show more Original Article

        Similar Articles

        Navigate

        • home

        More Information

        • Help

        Additional journals

        • All Topics

        Other Services

        • About

        © 2025 Neurosciences Journal Neurosciences is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3183. Print ISSN 1319-6138.

        Powered by HighWire